Company
Brisbane, QLD
Every investor coverage indicates participated in a round Ellume Health raised.
Companies Ellume Health acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Joanne Dunne | Administrator | SmartCompany |
| John Park | Administrator | SmartCompany |
| Scott Fry | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Ellume Health. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Queensland Covid test maker Ellume has been wound up after Gold Coast bidder Hough Consolidated failed to pay a deposit, collapsing its $56m takeover; creditors await an estimated return.
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.
Ellume's Australian operations have entered voluntary administration, with FTI Consulting appointed administrators; the US business continues. The Brisbane diagnostics maker earlier raised $5 million and won a big US government supply contract.
Also Startup Daily
Techboard's March 2022 roundup of Australian funding: megadeals by Immutable, Saluda Medical, Linktree and Zeller, many smaller raises, acquisitions, an IPO, several fund closes, and companies still seeking capital.
Also Australian FinTech
Australian rapid antigen test makers AnteoTech, Lumos Diagnostics and Ellume are exporting output while awaiting TGA approval, despite earlier Queensland and federal government funding, as politicians criticise the domestic shortage.